Intech Investment Management LLC Buys Shares of 7,270 Krystal Biotech, Inc. (NASDAQ:KRYS)

Intech Investment Management LLC purchased a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 7,270 shares of the company’s stock, valued at approximately $1,323,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Jamison Private Wealth Management Inc. purchased a new position in Krystal Biotech in the second quarter valued at about $28,000. GAMMA Investing LLC grew its stake in shares of Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after buying an additional 93 shares in the last quarter. Key Financial Inc acquired a new position in Krystal Biotech in the second quarter worth approximately $28,000. Blue Trust Inc. increased its holdings in Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after buying an additional 163 shares during the last quarter. Finally, Values First Advisors Inc. bought a new position in Krystal Biotech during the third quarter valued at approximately $53,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Chardan Capital increased their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Stifel Nicolaus raised their target price on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Citigroup increased their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Evercore ISI boosted their target price on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $202.29.

Krystal Biotech Stock Up 1.0 %

Shares of NASDAQ:KRYS opened at $196.52 on Wednesday. The company has a market cap of $5.65 billion, a price-to-earnings ratio of 111.03 and a beta of 0.82. The business has a 50 day moving average price of $179.69 and a 200 day moving average price of $183.09. Krystal Biotech, Inc. has a twelve month low of $99.00 and a twelve month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same quarter last year, the company posted ($0.67) earnings per share. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis. Analysts anticipate that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This trade represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).